HBV RNA可早期预测HBeAg阴性慢性乙肝患者对聚乙二醇干扰素α的应答
本研究基于国际随机对照试验(PARC研究),在133例HBeAg阴性慢性乙肝患者中动态检测HBV RNA水平,评估其预测PEG-IFN α-2a治疗应答的价值。结果显示,治疗12周时HBV RNA下降幅度在应答者中更大,且12周或24周HBV RNA高水平对应答具有高阴性预测值,提示HBV RNA可作为早期预测指标。
要点
- 基线HBV RNA均值4.4 log10 c/mL,治疗12周平均下降1.6 log10 c/mL。
- 12周HBV RNA>1700 c/mL预测无应答的阴性预测值为91%,24周为93%。
核心结论
- 在HBeAg阴性慢性乙肝患者接受PEG-IFN治疗过程中,HBV RNA快速显著下降,且与治疗应答及长期随访HBsAg清除相关。
研究设计与样本
- 基于国际随机对照试验(PARC研究,NCT00114361),纳入133例HBeAg阴性慢性乙肝患者,接受PEG-IFN α-2a治疗48周,随访至144周。
主要发现
- 基线HBV RNA平均值为4.4(SD 1.2)log10 c/mL,治疗12周平均下降-1.6(1.1)log10 c/mL。
- 12周时HBV RNA在144周HBsAg<100 IU/mL或HBsAg清除的患者中显著更低。
关键数值与推荐
- 应答定义为第72周HBV DNA<2000 IU/mL且ALT正常。
- 12周HBV RNA>1700 c/mL(3.2 log10 c/mL)提示应答可能性低,阴性预测值91%。
- 24周HBV RNA>1700 c/mL对无应答的阴性预测值为93%。
临床怎么用
- 治疗12周时检测HBV RNA,若>1700 c/mL可辅助识别PEG-IFN应答可能性低的患者,帮助早期治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B virus RNA (HBV-RNA) is a novel serum biomarker that correlates with transcription of intrahepatic covalently closed circular (cccDNA), which is an important target for pegylated interferon (PEG-IFN) and novel therapies for functional cure. We studied HBV-RNA kinetics following PEG-IFN treatment and its potential role as a predictor to response in HBeAg-negative chronic hepatitis B (CHB) patients. METHODS: HBV-RNA levels were measured in 133 HBeAg-negative CHB patients treated in an international randomized controlled trial (PARC study). Patients received PEG-IFN α-2a for 48 weeks. HBV-RNA was measured from baseline through week 144. Response was defined as HBV-DNA <2000 IU/mL and ALT normalization at week 72. Kinetics of HBV-RNA were compared with HBV-DNA, HBsAg, and HBcrAg. RESULTS: Mean HBV-RNA at baseline was 4.4 (standard deviation [SD] 1.2) log10 c/mL. At week 12, HBV-RNA declined by -1.6 (1.1) log10 c/mL. HBV-RNA showed a greater decline in responders compared to nonresponders early at week 12 (-2.0 [1.2] vs -1.5 [1.1] log10 c/mL, P = .04). HBV-RNA level above 1700 c/mL (3.2 log10 c/mL) had a negative predictive value of 91% at week 12 and 93% at week 24 (P = .01) for response. Overall, HBV-RNA showed a stronger correlation with HBV-DNA and HBcrAg (.82 and .80, P < .001) and a weak correlation with HBsAg (.25). At week 12, HBV-RNA was significantly lower among patients with lower HBsAg (<100 IU/mL) or HBsAg loss at week 144. CONCLUSIONS: During PEG-IFN treatment for HBeAg-negative CHB, HBV-RNA showed a fast and significant decline that correlates with treatment response and HBsAg loss at long-term follow-up. CLINICAL TRIALS REGISTRATION: NCT00114361.
引用
- Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. Clin Infect Dis. 2021. PMID: 31912157. doi:10.1093/cid/ciaa013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。